N-methyl-D-aspartate receptor antagonist MK-801 induced circling behavior in rats with unilateral striatal ischemic lesions or nigral 6-hydroxydopamine lesions. 1993

S Goto, and K Korematsu, and N Inoue, and K Yamada, and T Oyama, and S Nagahiro, and Y Ushio
Department of Neurosurgery, Kumamoto University Medical School, Japan.

The present study shows that systemic administration of the selective, non-competitive N-methyl-D-aspartate antagonist MK-801 [(+)-5-methyl-10,11-dihydroxy-5H-dibenzo (a,d)-cyclohepten-5,10-imine] dose-dependently induces ipsiversive rotational behavior in the rats with a unilateral striatal lesion produced by transient middle cerebral artery occlusion or in those with a unilateral nigrostriatal lesion produced by 6-hydroxydopamaine. In relation to a functional model of the basal ganglia-thalamocortical 'motor' circuit, the present data suggest that the striatum may be one of the most important sites where MK-801 acts in the basal ganglia, with its being responsible for the circling behavior of the animal models.

UI MeSH Term Description Entries
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D002546 Ischemic Attack, Transient Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6) Brain Stem Ischemia, Transient,Cerebral Ischemia, Transient,Crescendo Transient Ischemic Attacks,Transient Ischemic Attack,Anterior Circulation Transient Ischemic Attack,Brain Stem Transient Ischemic Attack,Brain TIA,Brainstem Ischemia, Transient,Brainstem Transient Ischemic Attack,Carotid Circulation Transient Ischemic Attack,Posterior Circulation Transient Ischemic Attack,TIA (Transient Ischemic Attack),Transient Ischemic Attack, Anterior Circulation,Transient Ischemic Attack, Brain Stem,Transient Ischemic Attack, Brainstem,Transient Ischemic Attack, Carotid Circulation,Transient Ischemic Attack, Posterior Circulation,Transient Ischemic Attack, Vertebrobasilar Circulation,Transient Ischemic Attacks, Crescendo,Vertebrobasilar Circulation Transient Ischemic Attack,Attack, Transient Ischemic,Attacks, Transient Ischemic,Brainstem Ischemias, Transient,Cerebral Ischemias, Transient,Ischemia, Transient Brainstem,Ischemia, Transient Cerebral,Ischemias, Transient Brainstem,Ischemias, Transient Cerebral,Ischemic Attacks, Transient,TIA, Brain,TIAs (Transient Ischemic Attack),Transient Brainstem Ischemia,Transient Cerebral Ischemia,Transient Cerebral Ischemias,Transient Ischemic Attacks
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013239 Stereotyped Behavior Relatively invariant mode of behavior elicited or determined by a particular situation; may be verbal, postural, or expressive. Behavior, Stereotyped,Behaviors, Stereotyped,Stereotyped Behaviors
D013378 Substantia Nigra The black substance in the ventral midbrain or the nucleus of cells containing the black substance. These cells produce DOPAMINE, an important neurotransmitter in regulation of the sensorimotor system and mood. The dark colored MELANIN is a by-product of dopamine synthesis. Nigra, Substantia,Nigras, Substantia,Substantia Nigras
D016194 Receptors, N-Methyl-D-Aspartate A class of ionotropic glutamate receptors characterized by affinity for N-methyl-D-aspartate. NMDA receptors have an allosteric binding site for glycine which must be occupied for the channel to open efficiently and a site within the channel itself to which magnesium ions bind in a voltage-dependent manner. The positive voltage dependence of channel conductance and the high permeability of the conducting channel to calcium ions (as well as to monovalent cations) are important in excitotoxicity and neuronal plasticity. N-Methyl-D-Aspartate Receptor,N-Methyl-D-Aspartate Receptors,NMDA Receptor,NMDA Receptor-Ionophore Complex,NMDA Receptors,Receptors, NMDA,N-Methylaspartate Receptors,Receptors, N-Methylaspartate,N Methyl D Aspartate Receptor,N Methyl D Aspartate Receptors,N Methylaspartate Receptors,NMDA Receptor Ionophore Complex,Receptor, N-Methyl-D-Aspartate,Receptor, NMDA,Receptors, N Methyl D Aspartate,Receptors, N Methylaspartate
D016291 Dizocilpine Maleate A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects. Dizocilpine,MK-801,MK 801,MK801
D016627 Oxidopamine A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals. 6-Hydroxydopamine,6-OHDA,Oxidopamine Hydrobromide,Oxidopamine Hydrochloride,6 Hydroxydopamine,Hydrobromide, Oxidopamine,Hydrochloride, Oxidopamine
D017072 Neostriatum The phylogenetically newer part of the CORPUS STRIATUM consisting of the CAUDATE NUCLEUS and PUTAMEN. It is often called simply the striatum.

Related Publications

S Goto, and K Korematsu, and N Inoue, and K Yamada, and T Oyama, and S Nagahiro, and Y Ushio
June 1976, European journal of pharmacology,
S Goto, and K Korematsu, and N Inoue, and K Yamada, and T Oyama, and S Nagahiro, and Y Ushio
June 1989, Hypertension (Dallas, Tex. : 1979),
S Goto, and K Korematsu, and N Inoue, and K Yamada, and T Oyama, and S Nagahiro, and Y Ushio
March 1989, Pharmacology, biochemistry, and behavior,
S Goto, and K Korematsu, and N Inoue, and K Yamada, and T Oyama, and S Nagahiro, and Y Ushio
January 2004, Neuroscience,
S Goto, and K Korematsu, and N Inoue, and K Yamada, and T Oyama, and S Nagahiro, and Y Ushio
October 1993, Journal of anesthesia,
S Goto, and K Korematsu, and N Inoue, and K Yamada, and T Oyama, and S Nagahiro, and Y Ushio
February 1990, Neuroscience letters,
S Goto, and K Korematsu, and N Inoue, and K Yamada, and T Oyama, and S Nagahiro, and Y Ushio
January 1998, Neuroscience letters,
S Goto, and K Korematsu, and N Inoue, and K Yamada, and T Oyama, and S Nagahiro, and Y Ushio
September 1986, Proceedings of the National Academy of Sciences of the United States of America,
S Goto, and K Korematsu, and N Inoue, and K Yamada, and T Oyama, and S Nagahiro, and Y Ushio
September 2011, Pharmacology, biochemistry, and behavior,
S Goto, and K Korematsu, and N Inoue, and K Yamada, and T Oyama, and S Nagahiro, and Y Ushio
December 1990, Pharmacology, biochemistry, and behavior,
Copied contents to your clipboard!